Haemolytic Disease of the Newborn Due to Anti‐Mt<sup>a</sup>

Field, T. E.; Wilson, Tracy; Dawes, Ben; Giles, Carolyn M.

doi:10.1111/j.1423-0410.1972.tb03990.x

Cited by 6 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other reports, the prevalence was 0% (0/1000), 0.42% (6/1435), and 0.94% (3/318) in Irish, Swiss, and Thai populations, respectively . In the Irish population, screening was performed with serum of the mother of the child affected by HDFN presented in the case report of Field et al The sources mentioning the prevalence in Swiss and Thai populations did not make mention of the origin of the anti‐Mt a used. To our knowledge, the prevalence of the Mt a antigen has not been studied in populations other than the aforementioned.…”

Section: Discussionmentioning

confidence: 97%

“…Two of these cases were severe, requiring RBC transfusion. Apart from these cases, there is only one other published description of HDFN caused by anti‐Mt a . The affected newborn in that case was born to a woman who had already given birth to another Mt(a+) child.…”

Section: Discussionmentioning

confidence: 99%

“…It was first described in 1962 by Swanson and named after Mr. Martin, the blood donor with the newly discovered antigen present on his red blood cells (RBCs) . Since its discovery, only two case reports describing a total of four cases of hemolytic disease of the fetus and newborn (HDFN) associated with this antibody have been published, highlighting its rarity . This paper reports on a hemolytic transfusion reaction (HTR) associated with anti‐Mt a .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Acute hemolytic transfusion reaction associated with anti‐Mt^a: case report and review of the literature

et al. 2019

View full text Add to dashboard Cite

BACKGROUND Mta (MNS14) is a low‐prevalence antigen of the MNS system. A few cases of hemolytic disease of the fetus and newborn caused by anti‐Mta have been reported in the literature, but up to now this antibody has never been associated with a hemolytic transfusion reaction (HTR). CASE REPORT A 38‐year‐old male with sickle cell disease undergoing exchange transfusion presented with shivering, nausea, dyspnea, and pain in the lower limbs. Biologic parameters showed increased hemolysis. The administered red blood cell (RBC) units had been issued by electronic crossmatch due to a negative antibody screening test. In the posttransfusion investigations, crossmatch of the transfused RBC units with the patient's serum showed incompatibility of one unit. The presence of an antibody against a low‐prevalence antigen was suspected and further serologic testing was performed for identification. RESULTS Anti‐Mta was identified in the patient's serum. The RBCs of the incompatible unit implicated in the HTR were Mt(a+). An eluate of a posttransfusion blood sample of the patient was nonreactive with the incompatible RBCs, and the direct antiglobulin test was negative. CONCLUSION To our knowledge, this is the first case report of an HTR associated with anti‐Mta.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Acute hemolytic transfusion reaction associated with anti‐Mt^a: case report and review of the literature

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, anti–Mt a has demonstrated clinical significance since it has caused severe HDN [5]. It is reasonable to expect that anti–Vr could cause HDN since Vr is well developed on cord cells.…”

Section: Discussionmentioning

confidence: 99%

“…The Mt a antigen occurs with an incidence ranging from 0.099% in African–Amercians to 0.943% in the Tai population [4]. The antigen is fully developed on cord RBCs and has caused severe hemolytic disease of the newborn (HDN) in 1 infant who required exchange transfusions [5]. To date, the Mt a antigen has not been found on M+N– RBCs and the presence of the Mt a antigen does not affect the expression of N or s antigens.…”

Section: Introductionmentioning

confidence: 99%

The MNS Blood Group Antigens, Vr (MNS12) and Mt<sup>a</sup> (MNS14), Each Arise from an Amino Acid Substitution on Glycophorin A

Storry

Coghlan

Poole³

et al. 2000

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: The antigens, Vr (MNS12) and Mt^a (MNS14), are low–incidence antigens of the MNS blood group system. The Vr antigen has been found only on the red blood cells (RBCs) of persons of Dutch ancestry whereas the Mt^a antigen has been found on the RBCs of persons from a wide geographic distribution. The objective of this study was to determine the molecular basis of Vr and Mt^a. Materials and Methods: Following RT–PCR amplification of total RNA isolated from one Vr+ person (G488) and one Mt(a+) person (GH), the genes encoding glycophorin A (GYPA) and glycophorin B (GYPB) were cloned and sequenced. To confirm the point mutation observed in the cDNA from G488 (Vr+), GYPA exon 3 was cloned and sequenced from the genomic DNA of G488 and a second unrelated Vr+ person (MU). A restriction fragment length polymorphism (RFLP) assay was used to analyze genomic DNA from 11 Mt(a+) persons (10 unrelated) following PCR amplification of GYPA exon 3. Results: The coding sequence of GYPB was normal in both G488 (Vr+) and GH (Mt(a+)). Sequencing data from GYPA clones derived from G488 showed to full length GYPA sequences: A normal GYPA M allele and a GYPA M allele with a point mutation 197C→A. Sequencing of GYPA exon 3 from G488 and MU confirmed the point mutation. Sequencing data drom GYPA clones derived from GH showed two full length GYPA sequences: a normal GYPA M allele and a GYPA N allele with a point mutation 230C→T. RFLP analysis based on the point mutation showed that DNA from 11 Mt(a+) samples were heterozygous for the point mutation. Conclusion: The Vr antigen arises from a point mutation 197C→A on GYPA which is predicted to change serine at position 47 to tyrosine. This change introduces a new α–chymotrypsin cleavage site. The Mt^a antigen arises from a point mutation 230C→T which is predicted to change threonine at position 58 to isoleucine.

show abstract

MNS Blood Group System

2002

Human Blood Groups

View full text Add to dashboard Cite

Haemolytic Disease of the Newborn Due to Anti‐Mt^a

Abstract: Abstract. The first case of haemolytic disease of the newborn due to anti‐Mta is described.

Cited by 6 publications

References 3 publications

Acute hemolytic transfusion reaction associated with anti‐Mt^a: case report and review of the literature

Acute hemolytic transfusion reaction associated with anti‐Mt^a: case report and review of the literature

The MNS Blood Group Antigens, Vr (MNS12) and Mt<sup>a</sup> (MNS14), Each Arise from an Amino Acid Substitution on Glycophorin A

MNS Blood Group System

Contact Info

Product

Resources

About

Haemolytic Disease of the Newborn Due to Anti‐Mta

Abstract: Abstract. The first case of haemolytic disease of the newborn due to anti‐Mta is described.

Cited by 6 publications

References 3 publications

Acute hemolytic transfusion reaction associated with anti‐Mta: case report and review of the literature

Acute hemolytic transfusion reaction associated with anti‐Mta: case report and review of the literature

The MNS Blood Group Antigens, Vr (MNS12) and Mt<sup>a</sup> (MNS14), Each Arise from an Amino Acid Substitution on Glycophorin A

MNS Blood Group System

Contact Info

Product

Resources

About

Haemolytic Disease of the Newborn Due to Anti‐Mt^a

Acute hemolytic transfusion reaction associated with anti‐Mt^a: case report and review of the literature

Acute hemolytic transfusion reaction associated with anti‐Mt^a: case report and review of the literature